Zymeworks/$ZYME
1D1W1MYTD1Y5YMAX
Capital at risk
About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
- Ticker
- $ZYME
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 231
- Headquarters
- Middletown, United States
- Website
- www.zymeworks.com
Zymeworks Metrics
BasicAdvanced
$1.9B
-
-$2.01
1.15
-
Price and volume
Market cap
$1.9B
Beta
1.15
52-week high
$31.34
52-week low
$15.49
Average daily volume
679K
Financial strength
Current ratio
6.316
Quick ratio
5.855
Long term debt to equity
0.158
Total debt to equity
0.199
Interest coverage (TTM)
-17.96%
Profitability
EBITDA (TTM)
-150.652
Gross margin (TTM)
-246.66%
Net profit margin (TTM)
-404.00%
Operating margin (TTM)
-418.99%
Effective tax rate (TTM)
0.92%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-24.14%
Return on equity (TTM)
-72.31%
Valuation
Price to revenue (TTM)
54.016
Price to book
23.86
Price to tangible book (TTM)
28.47
Price to free cash flow (TTM)
-16.617
Free cash flow yield (TTM)
-6.02%
Free cash flow per share (TTM)
-1.616
Growth
Revenue change (TTM)
-69.78%
Earnings per share change (TTM)
105.54%
3-year revenue growth (CAGR)
-56.39%
3-year earnings per share growth (CAGR)
-10.27%
What the Analysts think about Zymeworks
Analyst ratings (Buy, Hold, Sell) for Zymeworks stock.
Analyst projections of the future price of Zymeworks stock.
Bulls say / Bears say
Zymeworks’ pending $929 million acquisition of Theravance Biopharma will add the FDA-approved COPD drug Yupelri and accompanying profit-share royalties, expanding Zymeworks’ revenue base and diversifying beyond oncology upon closing expected in 2H 2026 (Reuters).
FDA approval of Ziihera® for first-line HER2+ gastroesophageal adenocarcinoma on August 25, 2026 triggered a $250 million milestone payment and unlocks up to $1.3 billion in additional milestones plus tiered royalties, validating Zymeworks’ Azymetric™ platform (Yahoo Finance).
Phase 3 HERIZON-GEA-01 trial results were published in The New England Journal of Medicine and presented at ASCO 2026, demonstrating durable survival benefits with zanidatamab combinations and supporting Ziihera as a new standard of care in HER2+ GEA (Business Wire).
Total revenue fell to $4.6 million in Q2 2026 from $48.7 million a year earlier, underscoring Zymeworks’ reliance on irregular collaboration milestones and modest royalty streams rather than stable product sales (Zymeworks Q2 Release).
Net loss widened to $45 million in Q2 2026 from a net income of $2.3 million in Q2 2025, driven by the absence of non-recurring collaboration revenue and $6.6 million of interest expense on a royalty-backed financing, highlighting profitability pressures (Zymeworks Q2 Release).
The second interim overall survival analysis for the pivotal HERIZON-GEA-01 trial is due in Q3 2026, posing binary clinical risk that could delay regulatory approval and associated milestone payments if results are disappointing (Zymeworks Q2 Release).
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.
Zymeworks Financial Performance
Revenues and expenses
Zymeworks Earnings Performance
Company profitability
Upcoming events
No upcoming events
Zymeworks News
AllArticlesVideos
Funds containing Zymeworks
AllUSDEURGBP
Fund name | Fund size | $ZYME weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.12% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.12% |
iShares Healthcare Innovation£DRDR | £1B | 0.12% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.11% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.